A phase 1/2 trial of MRG003+HX008 in advanced solid tumours, run by Lepu Biopharma Co., Ltd., now recruiting.
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05688605 by Lepu Biopharma Co., Ltd., with 18 participants planned, started 2022-06-30 and due to reach its primary completion in 2027-08. Interventions recorded: MRG003+HX008.
Shares Lepu Biopharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.